SHANGHAI, CHINA--(MARKET WIRE)--Jun 12, 2007 -- Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTC BB:SOBM.OB - News) is pleased to announce that the Chinese State Food and Drug Administration (SFDA) has certified the lyophilized recombinant human acidic fibroblast growth factor for external use (rhaFGF) production plant of Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. (SinoBiomed’s 82-percent owned subsidiary) as a Good Manufacturing Practice (GMP) facility.
